Viviana Gradinaru
California Institute of Technology
172 Papers
797 Citations
Viviana Gradinaru is an academic researcher from California Institute of Technology. The author has contributed to research in topics: Biology & Medicine. The author has an hindex of 49, co-authored 137 publications. Previous affiliations of Viviana Gradinaru include Laboratory of Molecular Biology & Howard Hughes Medical Institute.
Chat about Author
Papers
Machine learning-guided channelrhodopsin engineering enables minimally-invasive optogenetics
TL;DR: These engineered light-gated channelrhodopsins enable light-induced neuronal excitation without invasive intracranial surgery for virus delivery or fiber optic implantation, i.e. they enable minimally-invasive optogenetics.
19
Advances in AAV technology for delivering genetically encoded cargo to the nonhuman primate nervous system
Lillian Campos,Cynthia Mary Arokiaraj,Miguel R. Chuapoco,Xinhong Chen,Nick Goeden,Viviana Gradinaru,Andrew S. Fox +6 more
TL;DR: In this article , the authors outline recent advances in the development of adeno-associated viral vectors for optimized use in nonhuman primates, which can help open new avenues for study in translational neuroscience and further understand the primate brain.
18
Structural basis of receptor usage by the engineered capsid AAV-PHP.eB
TL;DR: Zinn et al. as discussed by the authors reported a 2.24-Å resolution cryo-electron microscopy structure of PHP.eB, revealing conformational differences from other 7-mer insertion capsid variants.
17
Targeting the lung epithelium after intravenous delivery by directed evolution of underexplored sites on the AAV capsid
TL;DR: In this paper , the surfaceexposed residues AA452-458 of AAV9 capsid proteins at the threefold axis of symmetry were used to identify AAV capsids targeted to the lung after intravenous delivery in mice.
15
Broad gene expression throughout the mouse and marmoset brain after intravenous delivery of engineered AAV capsids
Nicholas C. Flytzanis,Nick Goeden,David Goertsen,Alexander Cummins,James Pickel,Viviana Gradinaru +5 more
TL;DR: To achieve organ/cell-type specific targeting after intravenous delivery of viral vectors, a Cre-transgenic-based screening platform is employed for fast and efficient capsid selection, paired with sequential engineering of multiple surface-exposed loops to identify capsid variants that are enriched in the brain and detargeted from the liver in mice.